SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.

SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024 SPR Therapeutics and the SPRINT PNS System will be featured prominently at the North American Neuromodulation Society Annual Meeting with 11 abstracts.

New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023 Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain

Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing LOS ANGELES, Sept. 15, 2021 (GLOBE NEWSWIRE) -- September is Pain Awareness Month. Affecting more than 50 million Americans, chronic pain - both unmanaged and unmanaged, physical and emotional - is...